BioNTech CEO Ugur Sahin (Photo by ddp images/Sipa USA)
January 5, 2022 07:33 AM ESTUpdated 02:08 PM
Deals

BioN­Tech and Pfiz­er an­nounce $225M shin­gles vac­cine project, of­fer­ing mR­NA chal­lenger to Glax­o­SmithK­line's Shin­grix

Jason Mast

Editor

One of the biggest sto­ry­lines of biotech’s next half-decade will be where Mod­er­na, BioN­Tech and their grow­ing list of ri­vals push the mR­NA tech­nol­o­gy that’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times